Local administration of Type IV phosphodiesterase inhibitors for

Details Local administration of Type IV phosphodiesterase inhibitors for Local administration of Type IV phosphodiesterase inhibitors for

1999-11-10

2000-10-03

Reamer, James H.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

514263, 514274, 514253, 514245, 514303, 514390, 514357, 514277, 514332, 514334, 514337, 514339, 5142767, 5142804, 5142841, A61K 3155

Patent

active

061273635

ABSTRACT:
A method is provided for treating erectile dysfunction, e.g., vasculogenic erectile dysfunction such as vasculogenic impotence. The method involves the administration of a Type IV phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, wherein administration is local, i.e., transurethral, intracavernosal, topical or transdermal. A preferred mode of administration is transurethral. Pharmaceutical formulations and kits are provided as well.

REFERENCES:
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3933822 (1976-01-01), Broughton et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4666908 (1987-05-01), Hamilton
patent: 4801587 (1989-01-01), Voss et al.
patent: 5145852 (1992-09-01), Virag
patent: 5242391 (1993-09-01), Place et al.
patent: 5250534 (1993-10-01), Bell et al.
patent: 5272147 (1993-12-01), Bell et al.
patent: 5346901 (1994-09-01), Bell et al.
patent: 5426107 (1995-06-01), Bell et al.
patent: 5506347 (1996-04-01), Erion et al.
Bush et al. (1992), "Nitric Oxide is a Potent Relaxant of Human and Rabbit Corpus Cavernosum," The Journal of Urology 147: 1650-1655.
Doherty (1997), "Oral, Transdermal, and Transurethral Therapies for Erectile Dysfunction," Male Infertility and Dysfunction, Springer-Verlag New York, Inc., pp. 452-467.
Rajfer et al. (1992), "Nitric Oxide as a Mediator of Relaxation of the Corpus Cavernosum in Reponse to Nonadrenergic, Noncholinergic Neurotransmission," The New England Journal of Medicine 326(2):90-94.
Taher et al. (1992), "Cyclic Nucleotide Phosphodiesterase Activity in Human Cavernous Smooth Muscle and the Effect of Various Selective Inhibitors," International Journal of Impotence Research, Basic and Clinical Studies 4(2):11.
Trigo-Rocha et al. (1993), "The Role of Cyclic Adenosine Monophosphate, Cyclic Guanosine Monophosphate, Endothelium and Nonadrenergic, Noncholinergic Neurotransmission in Canine Penile Erection," The Journal of Urology 149:872-877.
Barnette et al. (1996), "Phosphodiesterase 4: Biological Underpinnings for the Design of Improved Inhibitors," Pharmacology Reviews and Communications 8:65-73.
Bivalacqua et al. (1999), "Potentiation of Erectile Response and cAMP Accumulation by Combination of Prostaglandin E.sub.1 and Rolipram, a Selective Inhibitor of a Type 4 Phosphodiesterase (PDE 4)," The Journal of Urology 162:1-8.
Boolell et al. (1996), "Sildenafil: An Orally Active Type 5 Cyclic GMP-Specific Phosphodiesterase Inhibitor for the Treatment of Penil Erectile Dysfunction," International Journal of Impotence Research 8:47-52.
Burnouf et al. (1998), "Phosphodiesterases 4 Inhibitors," Annual Reports in Medicinal Chemistry 33:91-109.
Christensen et al. (1996), "Molecular Aspects of Inhibitor Interaction with PDE4," Phosphodiesterase Inhibitors, Academic Press, Harcourt Brace and Company, Publishers, pp. 185-207.
Doherty (1999), "Phosphodiesterase 4 Inhibitors as Novel Anti-Infammatory Agents," Current Opin. Chem. Brol. 3(4):466-473.
Martinez-Pineiro et al. (1993), "Cyclic Guanosine Monophosphate Mediates Penile Erection in the Rat," European Urology 24:492-499.
McGarry et al. (1999), "Benzofuran Based PDE4 Inhibitors," Bioorganic & Medicinal Chemistry 7:1131-1139.
Muller et al. (1996), "Subtypes of the Type 4 cAMP Phosphodiesterases: Structure, Regulation and Selective Inhibition," Trends Pharm. Sci. 17(8):294-298.
Perrier et al. (1999), "Substituted Furans as Inhibitors of the PDE4 Enzyme," Bioorganic & Medicinal Chemistry Letters 9:323-326.
Polson et al. (1996), "Cyclic Nucleotide Phosphodieterases and Vascular Smooth Muscle," Annu. Rev. Pharmacol. Toxicol. 36:403-427.
Sparwasser et al. (1994), "Smooth Muscle Tone Regulation in Rabbit Cavernosal and Spongiosal Tissue by Cyclic AMP-and Cyclic GMP-Dependent Mechanisms," The Journal of Urology 152:2159-2163.
Stief et al. (1995), "Cyclic Nucleotide Phosphodieterase (PDE) Isoenzymes in Human Cavernous Smooth Muscle: Characterization and Functional Effects of PDE-Inhibitors in Vitro and In Vivo," International Journal of Impotence Research, Basic and Clinical Studies 7(1):6-7.
Taher et al. (1997), "Cyclic Nucleotide Phosphodieterase in Human Cavernous Smooth Muscle," World Journal of Urology 15:32-35.
Truss et al. (1998), "Phosphodiesterase Inhibitors in the Treatment of Erectile Dysfunction," Drugs of Today 34(9), summary only.

Affiliated with

Also associated with

Rating

Local administration of Type IV phosphodiesterase inhibitors for does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Local administration of Type IV phosphodiesterase inhibitors for, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Local administration of Type IV phosphodiesterase inhibitors for will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-195753